[1] Harris J M, Chess R B. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2003, 2:214221.
[2] Walsh G. Biopharmaceutical benchmarks. Nature Biotechnology, 2000, 18: 831833.
[3] Ryan S M, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opinion Drug Delivery, 2008, 5(4):371383.
[4] Veronese F M, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today, 2005, 10(21):14511458.
[5] Fishburn C S. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. Journal of Pharmaceutical Sciences, 2008, 97(10): 41674183.
[6]Veronese F M, Pasut G. PEGylation: Posttranslational bioengineering of protein biotherapeutics. Drug Discovery Today: Technologies, 2008, 5(23):e57e64.
[7] 王凤山, 赵婷, 袁勤生. 蛋白质和多肽的PEG定点修饰研究进展. 2008年中国药学会学术年会暨第八届中国药师周论文集, 2008:23212332.
[8] 付正明,王洪权,丁建新,等. 蛋白质多肽药物聚乙二醇定点修饰的研究进展. 军事医学科学院院刊, 2007,31(2):178182. Fu Z M, Wang H Q, Ding J X, et al. Bulletin of the Academy of Military Medical Sciences, 2007,31(2):178182.
[9] 董惠钧,姜俊云,郑立军,等. 蛋白药物聚乙二醇修饰技术研究进展. 中国生化药物杂志,2009,30 (3 ):199203. Dong H J, Jiang J Y, Zheng L J, et al. Chinese Journal of Biochemical Pharmaceutics,2009,30 (3 ):199203.
[10] Veronese F M, Pasut G. Polymerdrug conjugation, recent achievements and general strategies. Progress in Polymer Science, 2007, 32: 933961.
[11] Yoshioka Y, Tsutsumi Y, Ikemizu S, et al. Optimal sitespecific PEGylation of mutant TNFa improves its antitumor potency. Biochemical and Biophysical Research Communications, 2004, 315: 808814.
[12] Youn Y S, Kwon M J, Na D H, et al. Improved intrapulmonary delivery of sitespecific PEGylated salmon calcitonin: Optimization by PEG size selection. Journal of Controlled Release, 2008, 125:6875.
[13] Fee C J. Sizeexclusion reaction chromatography (SERC): A new technique for protein PEGylation. Biotechnology and Bioengineering, 2003, 82(2): 200206.
[14] Baran E T, Ozer N, Hasirci V. Solidphase enzyme modification via affinity chromatography. Journal of Chromatography B, 2003, 794:311322.
[15] Lee B K, Kwon J S, Kim H J, et al. Solidphase PEGylation of recombinant interferon alpha2a for sitespecific modification: process performance, characterization, and in vitro bioactivity. Bioconjugate Chemistry, 2007, 18(6):17281734.
[16] Suo X Y, Lu X L, Hu T, et al. A solidphase adsorption method for PEGylation of human serum albumin and staphylokinase: preparation, purification and biochemical characterization. Biotechnology Letters, 2009, 31:11911196.
[17] Suo X Y, Zheng C Y, Yu PZ, et al. Solid phase pegylation of hemoglobin. Artificial Cells, Blood Substitutes, and Biotechnology, 2009, 12:19.
[18] Hou B B, Li S R, Li X H, et al. Design, preparation and in vitro bioactivity of monopegylated recombinant hirudin. Chinese Journal of Chemical Engineering,2007,15(6):775780.
[19] 修志龙,李雪芹,李晓晖.一种利用阴离子交换柱辅助聚乙二醇修饰水蛭素的方法:中国专利,200810011554.6, 20081008. Xiu Z L, Li X Q, Li X H. Chinese Patent, 200810011554.6, 20081008.
[20] Lu Y A, Felix A M. Pegylated peptides II: Solidphase synthesis of amino, carboxy and sidechain pegylated peptides. International Journal of Peptide & Protein Research.,1994, 43(2):127138.
[21] Kinstler O, Molineux G, Treuheit M, et al. MonoNterminal poly (ethylene glycol)–protein conjugates. Advanced Drug Delivery Reviews, 2002, 54: 477485.
[22] Youn Y S, Na D H, Lee K C. Highyield production of biologically active monoPEGylated salmon calcitonin by sitespecific PEGylation. Journal of Controlled Release, 2007, 117: 371379.
[23] Youn Y S, Lee K C. Sitespecific PEGylation for highyield preparation of Lys21amine PEGylated growth hormonereleasing factor (GRF) (129) using a GRF(129) derivative FMOCprotected at Tyr1 and Lys12. Bioconjugate Chemistry, 2007, 18:500506.
[24] Youn Y S, Chae S Y, Lee S, et al. Evaluation of therapeutic potentials of sitespecific PEGylated glucagonlike peptide1 isomers as a type 2 antidiabetic treatment, insulinotropic activity, glucosestabilizing capability, and proteolytic stability. Biochemical Pharmacolocy, 2007, 73:8493.
[25] Chae S Y, Chun Y G, Lee S, et al. Pharmacokinetic and pharmacodynamic evaluation of sitespecific PEGylated glucagonlike peptide1 analogs as flexible postprandialglucose controllers. Journal of Pharmaceutical Sciences, 2009, 98(4): 15561567.
[26] Balan S, Choi J W, Godwin A, et al. Sitespecific PEGylation of protein disulfide bonds using a threecarbon bridge. Bioconjugate Chemistry, 2007, 18:6176.
[27] Balan S, Brocchini S, Godwin A, et al. Disulfide bridge based PEGylation of proteins. Advanced Drug Delivery Reviews, 2008, 60(1):312.
[28] 李智华,胡满仓,阎玲梅,等. 人白细胞介素11的定点聚乙二醇修饰. 中国生物工程杂志,2009,29(6):2024. Li Z H, Hu M C, Yan L M, et al. China Biotechnology, 2009,29(6):2024.
[29] Chi Y S, Zhang H B, Huang W L, et al. Microwaveassisted solid phase synthesis, PEGylation, and biological activity studies of glucagonlike peptide1(7–36) amide. Bioorganic & Medicinal Chemistry, 2008, 16:76077614.
[30] Fontana A, Spolaore B, Mero A, et al. Sitespecific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Advanced Drug Delivery Reviews, 2008, 60: 1328.
[31] Mero A, Spolaore B, Veronese F M, et al. Transglutaminasemediated PEGylation of proteins: direct identification of the sites of protein modificationby mass spectrometry using a novel monodisperse PEG. Bioconjugate Chemistry, 2009, 20 (2):384389.
[32] Foser S, Schacher A, Weyer K A, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α2a (PEGASYS). Protein Expression and Purification, 2003, 30:7887.
[33] Lee K C, Moon S C, Park M O, et al. Isolation, characterization, and stability of positional isomers of monoPEGylated salmon calcitonins. Pharmaceutical Research, 1999, 16:813818.
[34] Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormonereleasing hormone (GRF) analogues. Advanced Drug Delivery Reviews, 2003, 55:12791291.
[35] Youn Y S, Na D H, Yoo S D, et al. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycolmodified growth hormonereleasing factor (129). Journal of Chromatography A, 2004, 1061:4549.
[36]Na D H, Park E J, Jo Y W, et al. Capillary electrophoretic separation of highmolecularweight poly(ethylene glycol)modified proteins. Analytical Biochemistry, 2008, 373(2):207212.
[37] Veronese F M, Sacca B, Polverino de Laureto P, et al. New PEGs for peptide and protein modification, suitable for identification of the PEGylation site. Bioconjugate Chemistry, 2001, 12(1): 6270.
[38] Dhalluin C, Ross A, Huber W, et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEGInterferonα2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjugate Chemistry, 2005, 16 (3):518527.
[39] 胡远东,白坚石,焦克芳,等. PEG修饰牛血红蛋白的计算机模拟研究. 生物物理学 报,2000,16(2 ):315321. Hu Y D, Bai J S, Jiao K F, et al. Acta Biophysica Sinica,2000,16(2 ):315321.
[40] 赵军,李雪芹,修志龙. PEG在线定点修饰水蛭素及其修饰位点的理论预测与分析. 高等学校化学学报,2009,30(7): 14101416. Zhao J, Li X Q, Xiu Z L. Chemical Journal of Chinese Universities,2009,30(7): 14101416.
[41] Digilio G, Barbero L, Bracco C, et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormonereleasing factor, hGRF(129)NH2. Journal of the American Chemical Society, 2003, 125 (12):34583470.
[42] Svergun D I, Ekstrom F, Vandergriff K D, et al. Solution structure of poly(ethylene) glycolconjugated hemoglobin revealed by smallangle Xray scattering: implications for a new oxygen therapeutic. Biophysical Journal, 2008, 94: 173181.
[43] Dhalluin C, Ross A, Leuthold L A, et al. Structural and biophysical characterization of the 40 kDa PEGInterferonα2a and its individual positional isomers. Bioconjugate Chemistry, 2005, 16 (3):504517.
[44] Zloh M, Shaunak S, Balan S, et al. Identification and insertion of 3carbon bridges in protein disulfide bonds: a computational approach. Nature Protocols, 2007, 2:10701083. |